Syfovre (pegcetacoplan) is a brand-name eye injection that’s prescribed for geographic atrophy. The cost of the drug with and without insurance can depend on several factors, such as whether Syfovre ...
William Blair has initiated coverage on Apellis Pharmaceuticals, Inc. (NASDAQ:APLS) and notes that Apellis was the first company to successfully target complement C3, which has led to the approval of ...
On Tuesday, JP Morgan highlighted its survey related to Apellis Pharmaceuticals, Inc.’s (NASDAQ:APLS) Syfovre and Astellas Pharma Inc’s (OTC:ALPMF) (OTC:ALPMY) Izervay. On average, surveyed physicians ...
Syfovre (pegcetacoplan) is not known to interact with alcohol, other medications, or supplements. However, receiving the drug while you have certain health conditions may cause harmful effects.
The first 12 months on the market for Apellis’ geographic atrophy (GA) drug Syfovre have been a roller-coaster ride. And there’s still more loops to negotiate. On Tuesday, when Apellis presented its ...
The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
Despite witnessing modest growth in demand over the past three months, Apellis Pharmaceuticals’ complement inhibitor for geographic atrophy (GA), Syfovre, may have hit a performance “nadir” in 2024’s ...
SYFOVRE is the only approved GA treatment to demonstrate a visual function benefit in a prespecified endpoint Data presented at the Clinical Trials at the Summit Meeting In a prespecified ...
A Media Snippet accompanying this announcement is available by clicking on this link. WALTHAM, Mass., Nov. 04, 2023 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (APLS) today announced data from ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results